store at low temperature
store at -20 ℃
Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and VEGF165. Ranibizumab's ability to selectively target and neutralize VEGF-A isoforms has made it a crucial component of research and treatment strategies for wet wet age-related macular degeneration (AMD).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 328.00 | |
5 mg | In stock | $ 863.00 | |
10 mg | In stock | $ 1,380.00 |
Description | Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and VEGF165. Ranibizumab's ability to selectively target and neutralize VEGF-A isoforms has made it a crucial component of research and treatment strategies for wet wet age-related macular degeneration (AMD). |
Molecular Weight | 48 kDa |
CAS No. | 347396-82-1 |
store at low temperature
store at -20 ℃
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ranibizumab 347396-82-1 Angiogenesis Tyrosine Kinase/Adaptors VEGFR VEGF121 Vascular endothelial growth factor receptor AMD RG 6321 VEGF110 Inhibitor inhibit RG6321 RG-6321 anti-VEGF antibody age-related macular degeneration VEGF165 inhibitor